Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 29, Pages 4521-4530Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.29.7929
Keywords
-
Categories
Funding
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Onyx Pharmaceuticals
- Facet Biotech
Ask authors/readers for more resources
Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available